Overview
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Background
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Indication
For the treatment of pulmonary tuberculosis.
Associated Conditions
- Active Tuberculosis
- Late phase Tuberculosis
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/04/08 | Phase 2 | Not yet recruiting | Shandong University | ||
2025/03/13 | Phase 4 | Active, not recruiting | |||
2024/02/28 | Phase 1 | Recruiting | |||
2024/02/12 | Phase 3 | Recruiting | |||
2024/01/05 | Phase 3 | Not yet recruiting | |||
2022/07/12 | Phase 3 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | ||
2021/11/16 | Phase 1 | Recruiting | The Aurum Institute NPC | ||
2021/08/25 | Phase 4 | Not yet recruiting | Miguel Santín | ||
2021/01/11 | Phase 4 | Completed | |||
2020/09/16 | Phase 4 | Withdrawn |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| RPK Pharmaceuticals, Inc. | 53002-1718 | ORAL | 150 mg in 1 1 | 7/6/2018 | |
| A-S Medication Solutions | 50090-5063 | ORAL | 150 mg in 1 1 | 7/6/2018 | |
| sanofi-aventis U.S. LLC | 0088-2102 | ORAL | 150 mg in 1 1 | 7/6/2018 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Rifapentine Capsules | 国药准字H10940211 | 化学药品 | 胶囊剂 | 12/14/2020 | |
| Rifapentine Capsules | 国药准字H20133047 | 化学药品 | 胶囊剂 | 7/28/2022 | |
| Rifapentine Capsules | 国药准字H10940212 | 化学药品 | 胶囊剂 | 12/18/2020 | |
| Rifapentine Capsules | 国药准字H10940011 | 化学药品 | 胶囊剂 | 7/23/2020 | |
| Rifapentine Capsules | 国药准字H20093872 | 化学药品 | 胶囊剂 | 6/21/2019 | |
| Rifapentine Capsules | 国药准字H10940199 | 化学药品 | 胶囊剂 | 12/4/2019 | |
| Rifapentine Capsules | 国药准字H10940012 | 化学药品 | 胶囊剂 | 7/23/2020 | |
| Rifapentine Capsules | 国药准字H10840004 | 化学药品 | 胶囊剂 | 3/22/2024 | |
| Rifapentin Dispersible Tablets | 国药准字H20120045 | 化学药品 | 片剂 | 1/18/2022 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||